Nigeria: U.S., Nigeria Researchers to Give Better Estimate of Covid-19

A new study by a team of United States(US) and Nigerian scientists has reaffirmed the importance of validating SARS-CoV-2 assays using locally obtained samples to assess COVID-19 exposure in the population.

According to a statement issued by the US Embassy in Abuja, this is continuation of the US Government support for Nigeria's conduct of a household survey that determines the extent of COVID-19 transmission in the country.

The researchers conducted a laboratory-based investigation to validate SARS-CoV-2 assays using samples from COVID-19 survivors and other archived pre-pandemic samples available in Nigeria.

In the study tagged Validation of xMAP SARS-CoV-2 Multi-Antigen IgG assay in Nigeria ( published in the journal PLOS ONE, the researchers collected samples from individuals at different time points after the patients' initial COVID-19 RT-PCR (Reverse Transcription Polymerase Chain Reaction) positive result.

In addition, the researchers used archived plasma specimens stored before October 2019 and specimens from the 2018 US-supported Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS). Over 100 SARS-CoV-2 positive specimens and about 300 archived specimens were used to evaluate the assays' sensitivity and specificity, two crucial indicators of the accuracy of test results.

The team initially validated four SARS-CoV-2 serological assays, which show lower sensitivity than the manufacturers' results. Similarly, two assays targeting the most crucial structural components of SARS-CoV-2 (Nucleocapsid protein) indicated moderate to substantial cross-reactivity. Cross-reactivity is the presence of other pathogens in the samples, thereby affecting the test outcomes.

Dr. Nnaemeka Iriemenam is the paper's lead author and Deputy Chief of the US-CDC Nigeria Laboratory Branch. He said it is vital for countries preparing for COVID-19 sero-surveillance to validate SARS-CoV-2 serology assay using in-country specimens. The assays need to reflect the serologic profile of the population being tested to avoid wrong estimates.

This latest study follows previous studies by the same team. The conclusions are consistent with the Validation of Commercial SARS-CoV-2 Immunoassays in a Nigerian Population study published in Microbiology Spectrum 10.1128/Spectrum.00680-21, the statement added.

It is also in line with the Cross-Reactivity of Two SARS-CoV-2 Serological Assays in a Setting Where Malaria Is Endemic, published in American Society for Microbiology's Journal of Clinical Microbiology 10.1128/JCM.00514-21.

AllAfrica publishes around 600 reports a day from more than 100 news organizations and over 500 other institutions and individuals, representing a diversity of positions on every topic. We publish news and views ranging from vigorous opponents of governments to government publications and spokespersons. Publishers named above each report are responsible for their own content, which AllAfrica does not have the legal right to edit or correct.

Articles and commentaries that identify as the publisher are produced or commissioned by AllAfrica. To address comments or complaints, please Contact us.